Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma

Background:Tumour-infiltrating lymphocyte (TIL) therapy is showing great promise in the treatment of patients with advanced malignant melanoma. However, the translation of TIL therapy to non-melanoma tumours such as renal cell carcinoma has been less successful with a major constraint being the inability to reproducibly generate TILs from primary and metastatic tumour tissue.Methods:Primary and metastatic renal cell carcinoma biopsies were subjected to differential tumour disaggregation methods and procedures that stimulate the specific expansion of TILs tested to determine which reliably generated TIL maintained antitumour specificity.Results:Enzymatic or combined enzymatic/mechanical disaggregation resulted in equivalent numbers of TILs being liberated from renal cell carcinoma biopsies. Following mitogenic activation of the isolated TILs with anti-CD3/anti-CD28-coated paramagnetic beads, successful TIL expansion was achieved in 90% of initiated cultures. The frequency of T-cell recognition of autologous tumours was enhanced when tumours were disaggregated using the GentleMACS enzymatic/mechanical system.Conclusion:TILs can be consistently produced from renal cell carcinoma biopsies maintaining autologous tumour recognition after expansion in vitro. While the method of disaggregation has little impact on the success of TIL growth, methods that preserve the cell surface architecture facilitate TIL recognition of an autologous tumour, which is important in terms of characterising the functionality of the expanded TIL population.

• Publication year

  2015

• Venue

  British Journal of Cancer

• Publication date

  2015-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.2015.96PMID 25867267PMCID 4453687
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A role for CCL28–CCR3 in T-cell homing to the human upper airway mucosa

  2014cited by this paper
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

  2014cited by this paper
• Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

  2013cited by this paper
• Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes

  2013cited by this paper
• Potential Limitations of the NSG Humanized Mouse as a Model System to Optimize Engineered Human T cell Therapy for Cancer

  2013cited by this paper
• Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas

  2013cited by this paper
• CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

  2013cited by this paper
• Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails

  2013cited by this paper
• Paths to stemness: building the ultimate antitumour T cell

  2012cited by this paper
• Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

  2012cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  2010cited by this paper
• CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

  2010cited by this paper
• Cell-in-cell structures formed between human cancer cell lines and the cytotoxic regulatory T-cell line HOZOT.

  2010cited by this paper
• Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.

  2009cited by this paper
• Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy

  2008cited by this paper
• Copulsing tumor antigen‐pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen‐specific CD8+ T cells via Vγ9γδ T cell activation

  2008cited by this paper
• Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation.

  2008cited by this paper
• IFN-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection.

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival

  2007cited by this paper
• Peptidome from Renal Cell Carcinoma Contains Antigens Recognized by CD4+ T Cells and Shared among Tumors of Different Histology

  2006cited by this paper
• Tumor‐specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens

  2005cited by this paper
• Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy

  2005cited by this paper
• Tumor-Infiltrating Lymphocytes and Interleukin-2: Dose and Schedules of Administration in the Treatment of Metastatic Cancer

  2004cited by this paper
• Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients

  2003cited by this paper
• A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.

  2003cited by this paper
• Primary Polyclonal Human T Lymphocytes Targeted to Carcino-Embryonic Antigens and Neural Cell Adhesion Molecule Tumor Antigens by CD3ζ-Based Chimeric Immune Receptors

  2002cited by this paper
• Effect of Tumor-Infiltrating Lymphocyte Subsets on Prognosis and Susceptibility to Interferon Therapy in Patients with Renal Cell Carcinoma

  2002cited by this paper
• Characterization of Human Tumor-Infiltrating Lymphocytes Expanded in Hollow-Fiber Bioreactors for Immunotherapy of Cancer

  2001cited by this paper
• Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.

  2000cited by this paper
• Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

  1999influential reference
• Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.

  1997influential reference
• Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.

  1996cited by this paper
• Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.

  1995cited by this paper

• Establishment of a serum-free culture system with an optimized 5-interleukin cytokine cocktail and insulin to promote preferential CD8⁺ T-cell expansion.

  2026cites this paper
• From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma

  2026cites this paper
• Microfluidic technologies for enhancing the potency, predictability and affordability of adoptive cell therapies

  2025cites this paper
• Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions

  2025cites this paper
• Feasibility and Functional Reactivity of Expanded Tumor-infiltrating Lymphocytes from Non-clear-cell Renal Cell Carcinoma.

  2025cites this paper
• Efficient expansion of tumor-infiltrating lymphocytes from gynecologic cancer.

  2025cites this paper
• The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.

  2025cites this paper
• Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation

  2025cites this paper
• Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

  2024cites this paper
• Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies.

  2024cites this paper
• Advances and prospects in tumor infiltrating lymphocyte therapy

  2024cites this paper
• Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy

  2024cites this paper
• Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy

  2024cites this paper
• Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

  2023cites this paper
• Antigenic targets in clear cell renal cell carcinoma

  2023cites this paper
• Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

  2023cites this paper
• Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma

  2023cites this paper
• Tumor‐infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment

  2023cites this paper
• TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.

  2022cites this paper
• Using mass cytometry for the analysis of samples of the human airways

  2022cites this paper
• Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?

  2022cites this paper
• Current State of Cell Therapies for Genitourinary Malignancies

  2022cites this paper
• The Immune Microenvironment in Gastric Cancer: Prognostic Prediction

  2022cites this paper
• Isolating and cryopreserving pig skin cells for single-cell RNA sequencing study

  2022cites this paper
• Landscape of Immunotherapy in Genitourinary Malignancies.

  2021cites this paper
• Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy

  2021cites this paper
• Retargeting Interleukin-2 Signaling to NKG2D-Expressing Tumor Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy

  2021cites this paper
• Isolating and Cryo-Preserving Pig Skin Cells for Single Cell RNA Sequencing Study

  2021cites this paper
• T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production

  2021cites this paper
• Mapping the immune environment in clear cell renal carcinoma by single-cell genomics

  2021cites this paper
• Mapping the immune environment in clear cell renal carcinoma by single-cell genomics

  2021cites this paper
• Fabrication of a silicon μDicer for uniform microdissection of tissue samples

  2021cites this paper
• Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

  2020cites this paper
• Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors

  2020cites this paper
• Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer

  2020cites this paper
• Methods for Single-Cell Isolation and Preparation.

  2020cites this paper
• Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.

  2020cites this paper
• Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target

  2020cites this paper
• T cells expanded from renal cell carcinoma are tumor-reactive but fail to produce IFN-γ, TNF-α or IL-2

  2020cites this paper
• Oncolytic Virus Promotes Tumor-Reactive Infiltrating Lymphocytes for Adoptive Cell Therapy

  2020cites this paper
• Current Landscape of Immunotherapy in Genitourinary Malignancies.

  2020cites this paper
• Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy

  2020cites this paper
• Renal cancer-derived exosomes induce tumor immune tolerance by MDSCs-mediated antigen-specific immunosuppression

  2020cites this paper
• Title: Mapping the Immune Landscape of Clear Cell Renal Cell Carcinoma by Single-Cell RNA-seq

  2019cites this paper
• Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

  2019cites this paper
• Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma

  2019cites this paper
• Targeting immune cells for cancer therapy

  2019cites this paper
• Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio

  2019cites this paper
• CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect.

  2019cites this paper
• Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function

  2019cites this paper
• MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis

  2019cites this paper
• Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy

  2019cites this paper
• Mapping the Immune Landscape of Clear Cell Renal Cell Carcinoma by Single-Cell RNA-seq

  2019cites this paper
• Autotransplantation of T-lymphocytes as a tool for antigen-specific immunotherapy of oncological diseases

  2018cites this paper
• Immune markers to predict response to neoadjuvant chemoradiotherapy and identifying methods to incorporate immunotherapy in locally advanced rectal cancer

  2018cites this paper
• Аутотрансплантация Т-лимфоцитов как инструмент для антиген-специфической иммунотерапии онкологических заболеваний

  2018cites this paper
• Allogeneic Stem Cell Transplantation

  2018cites this paper
• Potential advantages of CD1‐restricted T cell immunotherapy in cancer

  2018cites this paper
• The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor

  2018cites this paper
• Experimental Considerations for Single-Cell RNA Sequencing Approaches

  2018cites this paper
• Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure.

  2018cites this paper
• Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells

  2018cites this paper
• Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality

  2018cites this paper
• T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy

  2018cites this paper
• Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy.

  2018cites this paper
• Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer

  2017cites this paper
• IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model

  2017cites this paper
• Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer

  2017cites this paper
• The Importance of Understanding & Designing Cellular Therapy Supply Chains

  2017cites this paper
• Improving adenovirus-based immunotherapies for treatment of solid tumors

  2017cites this paper
• Evolving adoptive cellular therapies in urological malignancies.

  2017cites this paper
• The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer

  2017cites this paper
• Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer.

  2016cites this paper
• Immunotherapy in kidney cancer: the past, present, and future

  2016cites this paper
• CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2016, Mainz, Germany

  2016cites this paper
• Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.

  2016cites this paper
• Immunological battlefield in gastric cancer and role of immunotherapies.

  2016cites this paper
• The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma

  2016cites this paper
• Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

  2015cites this paper
• CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

  2015cites this paper
• Adoptive T‐cell therapy for cancer: The era of engineered T cells

  2015cites this paper
• Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer

  2015cites this paper